Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

A Phase 2 trial of CKD-498 in female patients with androgenetic alopecia has completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• CKD-498

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Androgenetic Alopecia | Phase 2 | Status: COMPLETED